Literature DB >> 33990177

Identification of upregulated NF-κB inhibitor alpha and IRAK3 targeting lncRNA following intracranial aneurysm rupture-induced subarachnoid hemorrhage.

Wei Leng1, Dan Fan1, Zhong Ren1, Qiaoying Li2.   

Abstract

BACKGROUND: This study was performed to identify genes and lncRNAs involved in the pathogenesis of subarachnoid hemorrhage (SAH) from ruptured intracranial aneurysm (RIA).
METHODS: Microarray GSE36791 was downloaded from Gene Expression Omnibus (GEO) database followed by the identification of significantly different expressed RNAs (DERs, including lncRNA and mRNA) between patients with SAH and healthy individuals. Then, the functional analyses of DEmRNAs were conducted and weighted gene co-expression network analysis (WGCNA) was also performed to extract the modules associated with SAH. Following, the lncRNA-mRNA co-expression network was constructed and the gene set enrichment analysis (GSEA) was performed to screen key RNA biomarkers involved in the pathogenesis of SAH from RIA. We also verified the results in a bigger dataset GSE7337.
RESULTS: Totally, 561 DERs, including 25 DElncRNAs and 536 DEmRNAs, were identified. Functional analysis revealed that the DEmRNAs were mainly associated with immune response-associated GO-BP terms and KEGG pathways. Moreover, there were 6 modules significantly positive-correlated with SAH. The lncRNA-mRNA co-expression network contained 2 lncRNAs (LINC00265 and LINC00937) and 169 mRNAs. The GSEA analysis showed that these two lncRNAs were associated with three pathways (cytokine-cytokine receptor interaction, neurotrophin signaling pathway, and apoptosis). Additionally, IRAK3 and NFKBIA involved in the neurotrophin signaling pathway and apoptosis while IL1R2, IL18RAP and IL18R1 was associated with cytokine-cytokine receptor interaction pathway. The expression levels of these genes have the same trend in GSE36791 and GSE7337.
CONCLUSION: LINC00265 and LINC00937 may be implicated with the pathogenesis of SAH from RIA. They were involved in three important regulatory pathways. 5 mRNAs played important roles in the three pathways.

Entities:  

Year:  2021        PMID: 33990177     DOI: 10.1186/s12883-021-02156-1

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


  37 in total

1.  Effect of High-Dose Simvastatin on Cerebral Blood Flow and Static Autoregulation in Subarachnoid Hemorrhage.

Authors:  Michael N Diringer; Rajat Dhar; Michael Scalfani; Allyson R Zazulia; Michael Chicoine; William J Powers; Colin P Derdeyn
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

2.  Improved survival after non-traumatic subarachnoid haemorrhage with structured care pathways and modern intensive care.

Authors:  Sahar Wesali; Hanna C Persson; Björn Cederin; Katharina S Sunnerhagen
Journal:  Clin Neurol Neurosurg       Date:  2015-07-31       Impact factor: 1.876

3.  Haptoglobin phenotype predicts the development of focal and global cerebral vasospasm and may influence outcomes after aneurysmal subarachnoid hemorrhage.

Authors:  Jenna L Leclerc; Spiros Blackburn; Dan Neal; Nicholas V Mendez; Jeffrey A Wharton; Michael F Waters; Sylvain Doré
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

4.  Factors associated with clinical and radiological status on admission in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Daniel W Zumofen; Michel Roethlisberger; Rita Achermann; Schatlo Bawarjan; Martin N Stienen; Christian Fung; Donato D'Alonzo; Nicolai Maldaner; Andrea Ferrari; Marco V Corniola; Daniel Schoeni; Johannes Goldberg; Daniele Valsecchi; Thomas Robert; Rodolfo Maduri; Martin Seule; Jan-Karl Burkhardt; Serge Marbacher; Philippe Bijlenga; Kristine A Blackham; Heiner C Bucher; Luigi Mariani; Raphael Guzman
Journal:  Neurosurg Rev       Date:  2018-02-10       Impact factor: 3.042

5.  The burden, trends, and demographics of mortality from subarachnoid hemorrhage.

Authors:  S C Johnston; S Selvin; D R Gress
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

6.  Role of simvastatin in prevention of vasospasm and improving functional outcome after aneurysmal sub-arachnoid hemorrhage: a prospective, randomized, double-blind, placebo-controlled pilot trial.

Authors:  K Garg; S Sinha; S S Kale; P S Chandra; A Suri; M M Singh; R Kumar; M S Sharma; R M Pandey; B S Sharma; A K Mahapatra
Journal:  Br J Neurosurg       Date:  2013-01-08       Impact factor: 1.596

7.  Acute neurocardiogenic injury after subarachnoid hemorrhage.

Authors:  Nader M Banki; Alexander Kopelnik; Michael W Dae; Jacob Miss; Poyee Tung; Michael T Lawton; Barbara J Drew; Elyse Foster; Wade Smith; William W Parmley; Jonathan G Zaroff
Journal:  Circulation       Date:  2005-11-14       Impact factor: 29.690

Review 8.  Aneurysmal Subarachnoid Hemorrhage: Strategies for Preventing Vasospasm in the Intensive Care Unit.

Authors:  Michael N Diringer; Allyson R Zazulia
Journal:  Semin Respir Crit Care Med       Date:  2017-12-20       Impact factor: 3.119

9.  Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

Authors:  Jian Shen; Kai-Yuan Huang; Yu Zhu; Jian-Wei Pan; Hao Jiang; Yu-Xiang Weng; Ren-Ya Zhan
Journal:  J Neurosurg       Date:  2016-10-07       Impact factor: 5.115

10.  Systematic Review of Intrathecal Nicardipine for the Treatment of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage.

Authors:  Shaheryar Hafeez; Ramesh Grandhi
Journal:  Neurocrit Care       Date:  2019-10       Impact factor: 3.210

View more
  1 in total

1.  m6A regulator-mediated RNA methylation modification patterns and immune microenvironment infiltration characterization in patients with intracranial aneurysms.

Authors:  Aierpati Maimaiti; Mirzat Turhon; Xiaojiang Cheng; Riqing Su; Kaheerman Kadeer; Aximujiang Axier; Dilimulati Ailaiti; Yirizhati Aili; Rena Abudusalamu; Ajimu Kuerban; Zengliang Wang; Maimaitili Aisha
Journal:  Front Neurol       Date:  2022-08-05       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.